Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HHS Deputy Secretary Azar to depart

Executive Summary

Alex Azar leaves his HHS post Feb. 3 to return to the private sector. Before serving as deputy secretary, Azar was HHS general counsel from 2001 to 2005. He had been involved in implementing the Medicare prescription drug benefit and was on the HHS importation task force...

You may also be interested in...



Lilly leadership changes

Alex Azar II will join Lilly as senior VP-corporate affairs and communications, the company announces May 4. Previously, Azar served as HHS Deputy Secretary for two years ending in February (1"The Pink Sheet" Jan. 22, 2007, In Brief). The company also announces that Ann Nobles will be chief compliance officer. Nobles has been with Lilly for over 16 years, most recently serving as VP-Corporate Affairs...

Political Oversight Of Agency Guidances, Rules Slated For House Hearing

Two House subcommittees are planning a joint hearing on amended 1Executive Order 12866, which institutionalizes the review of federal agency regulations and guidance documents by presidential appointees rather than career agency staff

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS047948

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel